טוען...
Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines
Recombinant thrombomodulin (rTM) has pleiotrophic properties, including anti‐coagulation and anti‐inflammation; however, its effectiveness as a treatment for multiple sclerosis (MS) has not been evaluated fully. High mobility group box 1 (HMGB1) and proinflammatory cytokines, working as inflammatory...
שמור ב:
| הוצא לאור ב: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6037993/ https://ncbi.nlm.nih.gov/pubmed/29509323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13123 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|